Stockscreener 앱 받기
4.9135
1.46%
0.1235
전일 마감가:
$4.79
열려 있는:
$4.85
하루 거래량:
19,347
Relative Volume:
0.03
시가총액:
$279.30M
수익:
$192.64M
순이익/손실:
$2.51M
주가수익비율:
18.20
EPS:
0.27
순현금흐름:
$12.42M
1주 성능:
+1.04%
1개월 성능:
-3.57%
6개월 성능:
-7.78%
1년 성능:
+7.52%
1일 변동 폭
$4.82
$4.91
1주일 범위
$4.7105
$4.90
52주 변동 폭
$3.46
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.91 | 279.30M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.59 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.75 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.97 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.20 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.94 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Vanda’s VGT-1849A gets orphan designation for polycythemia vera - BioWorld Online
HC Wainwright Reiterates Buy Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity - Seeking Alpha
Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment - MarketWatch
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Vanda Pharmaceuticals Secures FDA Orphan Drug Status for Novel Blood Cancer Treatment VGT-1849A - StockTitan
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com - MarketBeat
FDA's Gastro Drug Fast-Track Denial Survives DC Circ. - Law360
US Penny Stocks To Watch In December 2024 - Simply Wall St
DC Circuit Affirms FDA's Fast-Track Denial of Vanda Stomach Drug - Bloomberg Law
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc. - Marketscreener.com
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
Vanda Expands Efforts to Pull Two Hetlioz Copies From US Shelves - Bloomberg Law
Vanda Pharmaceuticals (STU:VM4) EV-to-Revenue : -0.37 (As of Dec. 01, 2024) - GuruFocus.com
Massachusetts Financial Services Co. MA Purchases New Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Long Term Trading Analysis for (VNDA) - Stock Traders Daily
Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
New Strong Buy Stocks For November 14th - Barchart
Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan
BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz
Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review
Vanda: Q3 Earnings Snapshot - Middletown Press
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.19%
자본화:
|
볼륨(24시간):